Cell Therapeutics

Latest Headlines

Latest Headlines

Baxter and its controversial partner CTI claim a win in PhIII blood cancer study

Baxter and CTI BioPharma say they have come up with statistically significant topline data on the effectiveness and safety of pacritinib, their late-stage therapy for myelofibrosis. But after the biotech's many twists and turns taken trying to advance pixantrone over the years, a few longtime observers preferred to wait and see the actual numbers before deciding for themselves.

Cell Therapeutics gets a lift as Novartis deals are terminated

For years, Cell Therapeutics CEO Jim Bianco has boasted about the company's long-standing relationship with Novartis. But as of this morning, the relationship is history.

FDA lifts a partial hold on Cell Therapeutics' leukemia drug

Cell Therapeutics got some good news from the FDA to start 2014. The agency has lifted a partial hold on tosedostat (IND 075503), giving the Seattle-based biotech a green light for all clinical studies of the cancer drug.

Baxter bets $60M on Cell Therapeutics' blood cancer drug

Long-troubled biotech Cell Therapeutics has landed a big-name partner for its Phase III myelofibrosis drug, convincing Baxter to shell out $60 million upfront for a cut of pacritinib.

FDA clamps partial hold on Cell Therapeutics trial after patient dies

Cell Therapeutics today announced that the FDA had put a partial clinical hold on its study of the experimental blood cancer drug tosedostat after the death of one of the patients in a clinical trial.

UPDATED: Cell Therapeutics lands myelofibrosis drug with $30M upfront

In addition to the $30 million upfront for the Singapore-based biotech, CEO Jim Bianco committed the company to an unspecified set of milestones for the treatment.

Cell Therapeutics calls retreat on bloodied pixantrone app

Two years after Cell Therapeutics ($CTIC) took one of the worst regulatory beatings of the decade at the time the FDA and its experts rejected the company's cancer drug pixantrone, the Seattle-based

Battered Cell Therapeutics pays $5M to in-license AML drug

Bruised and battered by its setback on pixantrone, Cell Therapeutics ($CTIC) is adding a new drug to its pipeline, paying $5 million upfront to license the North, Central and South American rights to

Cell Therapeutics raises $25M

Cell Therapeutics has raised $25 million by granting preferred stock and warrants to a single unnamed institutional investor. In a statement, the company says it intends to use the net proceeds from

Cell Therapeutics ($CTIC) appeals FDA decision on pixantrone

Cell Therapeutics said today that, as planned, it's submitted a formal appeal to the FDA regarding the agency's decision to reject pixantrone, an experimental treatment for relapsed/refractory